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Early diagnosisBreast cancer remains the most leading cause of death among women worldwide. Common methods for di-
agnosis and surveillance include mammography, histopathology and blood tests. The major drawback of
mammography is the high rate of false reports, aside from the risk from repeated exposure to harmful ioniz-
ing radiations; histopathology is time consuming and often prone to subjective interpretations; blood-based
tests are attractive, but lack the sensitivity and speciﬁcity. Obviously, more sensitive biomarkers for early de-
tection and molecular targets for better treating breast cancer are urgently needed. Fortunately, molecular
level ‘omics’ diagnosis is becoming increasingly popular; metabolomics, diagnosis based on ‘metabolic ﬁnger-
printing’ may provide clinically useful biomarkers applied toward identifying metabolic alterations and has
introduced new insights into the pathology of breast cancer. By applying advanced analytical and statistical
tools, metabolomics involves the comprehensive proﬁling of the full complement of low molecular weight
compounds in a biological system and could classify the basis of tumor biology of breast cancer, to identify
new prognostic and predictive markers and discover new targets for future therapeutic interventions. This
advanced bioanalytic methods may now open new avenues for diagnostics in cancer via discovery of bio-
markers. In this review we take a closer look at the metabolomics used within the ﬁeld of breast cancer di-
agnosis. Further, we highlight the most interesting metabolomics publications and discuss these in detail;
additional studies are mentioned as a reference for the interested reader. A general trend is an increased
focus on biological interpretation rather than merely the ability to classify samples.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license. Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
2. Metabolomics technologies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
3. Potential role of metabolites . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
4. Metabolomics features of breast cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
5. Bringing metabolomics into breast cancer research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
6. Metabolomics studies on breast cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
7. Conclusions and future perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Competing interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6f Serum Pharmacochemistry,
oad 24, Harbin 150040, China.
wangls@126.com (X.-J.Wang).
.V. Open access under CC BY-NC-ND license1. Introduction
Breast cancer belongs to the most frequent and severe cancer types
inwomenworldwide and its recurrence rates are very high [1]. The bur-
den of breast cancer is growingworldwide andwith it amore desperate
need for better tools to detect, diagnose and monitor the disease is re-
quired. The gold standard method for identifying patients with breast
cancer is the mammography, histopathology and blood tests [2–4].
However, these tests are not widely used as a risk assessment tool. 
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speciﬁcity. Metabolomics, a dynamic portrait of the metabolic status of
living systems, offers potential advantages that classically diagnose ap-
proaches that did not based on the discovery of a suite clinically rele-
vant biomarker [5,6]. Because small changes in living systems can lead
to large changes in metabolite levels, the metabolome can be regarded
as the ampliﬁed output of a biological system. Monitoring ﬂuctuations
of certain metabolites in body ﬂuids, has become an important way
to detect early stages in breast cancer [7]. Moreover, metabolomics
approaches are likely to be used to screen for potential diagnostic and
prognostic biomarkers of breast cancer [8].
Recent metabolomics studies have improved the understanding of
the basic mechanisms underlying cancer pathogenesis, which will
help to improve treatment strategies [9]. It aimed at characterizing
the metabolism of breast cancer to identify new biomarkers and new
targets for therapeutic interventions. A comprehensive coverage of
metabolism can be achieved by a combination of analytical approaches.
The most popular approaches for metabolomics involve mass spec-
trometry (MS), and nuclear magnetic resonance (NMR) spectroscopy
[10]. Over the past 10 years, continuous progress in the application
of NMR spectroscopy and MS to the detection, diagnosis and charac-
terization of human breast cancer has turned what began as scientiﬁc
curiosity into a useful clinical option. This technology permits simulta-
neous monitoring of many hundreds, or thousands, as well as func-
tional monitoring of multiple pivotal cellular pathways. Development of
metabolomics platform has made it possible to acquire high-throughput
proﬁles of potential biomarkers [11,12].
Emerging metabolomics is increasingly being used for breast can-
cer research and personalized medicine; it has provided new oppor-
tunities in the molecular analysis of human breast cancer with
unprecedented speed and detail [13]. This approach has the potential
to provide more information about the pathophysiological status of
an organism and distinguish breast cancer stages [14,15]. Meta-
bolomics biomarkers can potentially lead to breast cancer screening
and diagnosis and may provide useful information on the cancer
type and the disease's stage of progression. It has just begun to
enter the mainstream of cancer diagnostics and therapeutics. In this
review we intend to explore the potential role of metabolomics in
understanding breast cancer process, reﬁning its characterization
and searching for predictive biomarkers, highlighting the poten-
tial value of metabolomics for the noninvasive analysis of breast
cancer.
2. Metabolomics technologies
With technological advances in analytical techniques, the ability to
measure low-molecular-weight metabolites in a bioﬂuid provides a
powerful platform for identifying metabolites that are uniquely corre-
lated with a speciﬁc human disease [16]. Technological developments
are the driving force for advances in metabolomics, and identifying
novel changes in speciﬁc metabolites. A key task in cancer medicine is
to detect the disease as early as possible. In order to achieve this,
many new technologies have been developed for cancer biomarker dis-
covery [17]. Nuclearmagnetic resonance (NMR) spectroscopy andmass
spectrometry (MS) are themain analytical spectroscopic approaches in
metabolic proﬁling, usually offering complementary information, but
with different performance characteristics. Their complementary na-
ture makes the combination particularly attractive and can provide
complementary snapshots of the metabolome of body ﬂuids such as
plasma, urine or cerebrospinal ﬂuid [18]. High-deﬁnition MS has been
carried out to obtain comprehensivemetabolite proﬁling and pathways
of large biological data sets. MS tends to have much higher analytical
sensitivity, and enables broader surveys of the metabolome either in a
targeted or nontargeted manner. Because no single analytical method
can accommodate the chemical diversity of the entire metabolome;
thus, a multiplatform approach may provide a more comprehensiveunderstanding of metabolic alterations [19]. A combined analytical
approach can improve the potential for providing reliable methods to
detect metabolic proﬁle alterations in a biological specimen. In the
study by Asiago et al., using a combination of NMR and GC × GC–MS
methods, the metabolite proﬁles of 257 serum samples from 56 breast
cancer patients were analyzed and elevenmetabolitemarkers provided
a sensitivity of 86% and a speciﬁcity of 84% [20]. The combination of
two advanced analytical methods, NMR and MS, provides a powerful
approach for the early detection of recurrent breast cancer. Additionally,
an improvedmetabolic proﬁle obtained by combiningMS and NMR ap-
proach may be useful to achieve more accurate disease detection and
gainmore insight regarding breast cancermechanisms and biology [21].
3. Potential role of metabolites
Metabolomics capitalizes on the unique presence and concentra-
tion of small molecules in body ﬂuids to construct a ‘ﬁngerprint’
that can be unique to the individuals, including health and disease
states. It has been increasingly applied to discover biomarkers, identify
perturbed pathways, diagnose diseases, and measure the response to
treatment [22]. In the area of breast cancer, the integrated analysis of
metabolites may provide a powerful platform for detecting changes
related to cancer diagnosis and discovering novel biomarkers [23].
Biomarkers are biological characteristics that are objectively measured
and evaluated as indicators of pathological processes [24]. It is a biolog-
icalmolecule found in body ﬂuids that can be a sign of a disease, and has
been widely used in clinical practice for the diagnosis, assessment of
severity and response to therapy in a number of clinical disease states.
Analyzing metabolic differences between unperturbed and perturbed
systems, such as healthy volunteers and patients with a disease, can lead
to insights into the underlying pathology [25]. Assessment of a biological
system by means of global and non-targeted metabolomics provides the
investigator with molecular information that is close to the phenotype.
Biomarker discovery is one of the newly emerging innovations in the
diagnosis and treatment of cancer and many other diseases. With ad-
vances inmethods and technology, togetherwith the considerable efforts
to ﬁnd early and novel diagnostic breast cancer biomarkers, many candi-
dateswill be discovered; leading to early diagnosis, detection,monitoring
and efﬁcient treatment of breast cancers [26]. More speciﬁcally, meta-
bolomics has a global and non-invasive analysis of biomarkers that are in-
dicators of pathogenic process, thereby helping to monitor treatment
response [27]. Recently, a variety of multiple biomarkers reﬂecting
breast cancer pathologies have been developed and have the potential
to serve an important role in diagnosis and management of human
conditions.
4. Metabolomics features of breast cancer
Understanding the metabolome will not only provide insights
into the critical sites of regulation in health promotion, but will
also assist in identifying intermediate or surrogate cancer bio-
markers for establishing preventative or therapeutic approaches for
health. Metabolomics increased our knowledge of the dysregulated
metabolic pathways associated with progression of diseases and
provided potentially new therapeutic strategies targeting these
pathways, through our understanding about the distinct and com-
plete metabolic footprints of breast cancer [28]. Over the last few
years, there has been a rapidly growing number of metabolomics
applications aimed at ﬁnding biomarkers which could assist diagno-
sis, provide therapy guidance, and evaluate response to therapy for
particular breast cancer. Metabolite changes that were observed in
diseased individuals as a primary indicator have been an important
part of clinical practice [29]. This dynamic, simultaneous assessment
of thousands of metabolites allows identiﬁcation of the presence,
concentration and ﬂuxes of speciﬁc metabolites, and recognition
of the critical metabolic pathways recruited in carcinogenesis.
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insights into both the intercellular environment and host/tumor
interaction, allowing recognition of new biomarkers for diagnosis
and prediction of outcome, and new therapy targets. Metabolomics
has recently moved into one of the cornerstones of postgenomics
for the quantitative analysis and unbiased identiﬁcation of small
molecular metabolites which could yield important information
about a person's disease [30].
5. Bringing metabolomics into breast cancer research
Some studies have demonstrated that patient outcome of breast
cancer is substantially inﬂuenced by cancer stage at the time of diag-
nosis [31]. For example, patients with early stage breast cancer have a
signiﬁcant higher 5-year survival rates compared to patients diag-
nosed at late stage. Thus, it is important to develop effective methods
for early diagnosis as well as for precise staging of this disease pro-
cess. Although traditional test remains the most effective means to di-
agnose breast cancer, this approach generally suffers from poor
patient compliance. As such, it is imperative to develop accurate
and speciﬁc tests that utilize more convenient approaches. Many dis-
eases result in speciﬁc and characteristic changes in the biochemical
proﬁles of biological ﬂuids prior to the development of clinical symp-
toms [32]. These changes are often useful diagnostic and prognostic
biomarkers. Identifying biomarkers that can be used for the early de-
tection of breast cancer will result in more efﬁcient treatments, re-
duction in suffering, and lower mortality rates. An ideal screening
test should be non-invasive with high sensitivity and speciﬁcity.
Metabolomics is the upcoming new science in the omics ﬁeld with
the potential to further increment our knowledge of cancer biology
[33]. It has recently emerged as a novel method of breast cancer de-
tection owing to its ability to monitor changes in the metabolic signa-
ture that reﬂect changes in phenotype and function [34].
The translational value of metabolomics in the breast cancer stud-
ies has been demonstrated by the identiﬁcation of diagnostic and
prognostic biomarkers [35–38]. To become a clinically approved
test, a potential biomarker should be conﬁrmed and validated using
hundreds of specimens and should be reproducible, speciﬁc, and
sensitive. The accumulation of information from novel metabolomics
technologies comes with substantial hope and expectations that
these approaches will yield novel insights into breast cancer process-
es [39,40]. Integration of metabolomics-based diagnostic principles
into the breast cancer might be the direction to enable a revolution
for future health care, also perhaps it is time to embrace the arrival
of ‘Breast Cancer-OMICS’ era.
6. Metabolomics studies on breast cancer
Metabolomics has potential power to enhance our understanding of
the root causes of breast cancer, and provides a detailed snapshot of the
body's processes at any particular point in time, and opens up the possi-
bility of monitoring health and disease, prevention and treatment. In
order to expand themetabolite proﬁling capabilities to breast cancer, sev-
eral recent studies have developed. The metabolites as the end products
of cellular processes, are closely linked to phenotypes. Five potential
urinary biomarkers were successfully identiﬁed for breast cancer with
high accuracy [41]. The combinatorial effects amongmultiple biomarkers
can enhance discriminative power for breast cancer. The proposed urine
metabolomics method was applied to select candidate biomarkers from
50 breast cancer patients and 50 normal persons [42]. Among the altered
metabolic pathways, four metabolic biomarkers such as homovanillate,
4-hydroxyphenylacetate, 5-hydroxyindoleacetate and urea, were identi-
ﬁed. Urine samples from 85 breast cancer women and healthy controls
were analyzed to assess the metabolic proﬁles of nucleosides [43], and a
valid set of 35 candidates was selected. Based on this approach, ultimateestimates for sensitivity and speciﬁcity of 83.5% and 90.6% were obtained
for best prediction of breast cancer.
A comprehensive metabolic map of breast cancer was constructed
by GC–TOFMS analysis [44]. A total number of 368 were detected and
signiﬁcantly changed between cancer and normal tissues. These meta-
bolites are promising biomarkers for medical screening. Speciﬁcally,
the cytidine-5-monophosphate/pentadecanoic acid ratio was the most
signiﬁcant discriminator and allowed detection with a sensitivity of
94.8% and a speciﬁcity of 93.9%. Changes in lipid metabolism are an im-
portant and characterized hallmark of cancer. Metabolomics analysis by
GC–MS showed that sn-glycerol-3-phosphate, was elevated in breast
cancer compared to normal breast tissue [45]. In a subsequent study,
Li M et al. performed metabolomics studies on breast tissue samples
[46]. It showed that cancer and non-cancer samples can be discriminat-
ed very well with OPLS-DAmultivariate model. A subsequent blind test
showed 69% sensitivity and 94% speciﬁcity in the prediction of the
cancer status. A spectral analysis showed that in taurine- and choline-
containing compounds are elevated. In the study done by Giskeødegård
GF et al., the relationship between themetabolite proﬁles of breast can-
cer tissue and 5-year survival had been examined [47]. Higher levels of
glycine and lactate were found to be associated with lower survival
rates by both multivariate analyses and spectral integration, and are
suggested as biomarkers for breast cancer prognosis. Results imply
that the metabolic state of a tumor may provide additional information
concerning breast cancer prognosis.
Metabolic phenotypes of breast cancers in urine were investigated
[48]. Intermediates of the tricarboxylic acid cycle and metabolites re-
lating to energy metabolism, amino acids, and gut microbial meta-
bolism were perturbed and illustrated that urinary metabolomics may
be useful for detecting early-stage breast cancer. Forty-four early breast
cancer patients with pre- and postoperative serum samples had
metabolomics assessment [49]. Innate serummetabolomics differences
exist between early andmetastatic patients. Preoperative patients were
identiﬁed with 75% sensitivity, 69% speciﬁcity and 72% predictive
accuracy. Biomarkers are emerging as determinants of breast cancer
prognosis. Work done by Simpson et al. demonstrated that sensitive
histone modiﬁcations and corresponding histone modifying enzymes
can be used as diagnostic and prognostic biomarkers for breast cancer
[50].
The non-targeted qualitative proﬁling was ﬁrst achieved to get
metabolic patterns of collected samples and the targeted quantita-
tive analysis focused on hormonal metabolism was also conducted
[51]. Two known biomarkers, i.e., 5-hydroxymethyl-2-deoxyuridine
and 8-hydroxy-2-deoxyguanosine, in breast cancer were also con-
ﬁrmed using the present methods. These cancer markers are highly
related to metabolites which are responsible for oxidative DNA dam-
age and DNA methylation process. A high resolution MS-based
metabolomics has been implemented to ﬁnd biologically signiﬁcant
metabolite biomarkers in breast cancer [52]. Finally, a set of 12 me-
tabolites was identiﬁed as potential biomarkers including amino
acids, organic acids, and nucleosides, and revealed elevated trypto-
phan and nucleoside metabolism as well as protein degradation in
breast cancer patients. It demonstrates the advantages of integrating
metabolic networks with metabolomics for ﬁnding signiﬁcant po-
tential biomarkers.
Metabolomics, a high-throughput global metabolite analysis, has
shown substantial evidence to support its emerging role in breast
cancer diagnosis, recurrence, prognosis, and identifying novel cancer
biomarkers as well as developing cancer therapeutics [53]. Recent de-
velopments in the area of metabolic analysis may help to close the
gap between clinical metabolomics research and the development
of cancer metabolome [54]. Any ﬁndings associated with relevance
to breast cancer, once passed to the clinical level, will be eventually
combined with other diagnostic approaches to hopefully reach the
100% detection level for high-risk patients. Recent advances in
metabolomics along with the novel strategies to analyze, understand,
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nity in a very effective manner. We predict an intensiﬁed use of
metabolomics screens in clinical and preclinical studies focusing on
the onset and progression of breast cancer development.
7. Conclusions and future perspectives
Elimination of cancer in the 21st century is likely to depend not only
onmore effective individualized treatment, but also upon earlier detec-
tion and prevention. Breast cancer is the most common cancer in
womenworldwide and the high prevalence of breast cancer has caused
a huge burden on the modern society, and the development of new
technologies for better understanding of the molecular changes is es-
sential. There is still a lack of reliable biomarkers indicative of metabolic
alterations, highlighting the need for the development of early diagnos-
tic and prognostic markers for breast cancer. Metabolomics has the
potential to generate novel noninvasive diagnostic tests, based on bio-
markers of disease, which are simple and cost effective yet retain high
sensitivity and speciﬁcity characteristics. In future work, these potential
biomarkers should be further validated with a large enough patient
cohort to achieve earlier diagnosis of breast cancer. To enable a better
stratiﬁcation of patients, it is important to identify the pathways that
are relevant for tumor progression and therapy response and to deter-
mine biomarkers that could be used to monitor the activity of those
pathways. A deeper understanding of global perturbations in biochem-
ical pathways could provide valuable insights aboutmechanisms of dis-
ease, prognostic, and diagnostic biomarkers. It will lead to new insights
into themechanisms of cancer progression and cancer patientmanage-
ment through improved molecular diagnostics leading to improved
therapeutic concepts by selection of effective drugs as part of systems
medicine. This improves the likelihood that genuine metabolic bio-
markers for breast cancer can be detected and validated, and will even-
tually lead to diagnostic toolkits that will facilitate a muchmore precise
predictive and prognostic assessment.
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